FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials
Authors:
- Fausto PetrelliFPFausto Petrelli
- Karen BorgonovoKBKaren Borgonovo
- Mary CabidduMCMary Cabiddu
- Mara GhilardiMGMara Ghilardi
- Veronica LonatiVLVeronica Lonati
- Federica MasperoFMFederica Maspero
- Maria Grazia SautaMSMaria Grazia Sauta
- Giordano Domenico BerettaGBGiordano Domenico Beretta
- Sandro BarniSBSandro Barni
- 1 September 2013
- journal article
- review article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 12 (3) , 145-151
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysisBMC Cancer, 2012
- Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroupsBMC Cancer, 2012
- Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal CancerJournal of Clinical Oncology, 2012
- Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)British Journal of Cancer, 2012
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306Annals of Oncology, 2012
- Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancerBMC Cancer, 2011
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancerBritish Journal of Cancer, 2010
- Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trialBritish Journal of Cancer, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008